Search Results - "Suman, J"

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 by Perez, Edith A, Romond, Edward H, Suman, Vera J, Jeong, Jong-Hyeon, Sledge, George, Geyer, Jr, Charles E, Martino, Silvana, Rastogi, Priya, Gralow, Julie, Swain, Sandra M, Winer, Eric P, Colon-Otero, Gerardo, Davidson, Nancy E, Mamounas, Eleftherios, Zujewski, Jo Anne, Wolmark, Norman

“…Positive interim analysis findings from four large adjuvant trials evaluating trastuzumab in patients with early-stage human epidermal growth factor receptor 2…”
Get full text

The role of root exuded low molecular weight organic anions in facilitating petroleum hydrocarbon degradation: Current knowledge and future directions by Martin, Belinda C., George, Suman J., Price, Charles A., Ryan, Megan H., Tibbett, Mark

“…Rhizoremediation is a bioremediation technique whereby enhanced microbial degradation of organic contaminants occurs within the plant root zone (rhizosphere)…”
Get full text

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) by Ellis, Matthew J, Suman, Vera J, Hoog, Jeremy, Goncalves, Rodrigo, Sanati, Souzan, Creighton, Chad J, DeSchryver, Katherine, Crouch, Erika, Brink, Amy, Watson, Mark, Luo, Jingqin, Tao, Yu, Barnes, Michael, Dowsett, Mitchell, Budd, G Thomas, Winer, Eric, Silverman, Paula, Esserman, Laura, Carey, Lisa, Ma, Cynthia X, Unzeitig, Gary, Pluard, Timothy, Whitworth, Pat, Babiera, Gildy, Guenther, J Michael, Dayao, Zoneddy, Ota, David, Leitch, Marilyn, Olson, Jr, John A, Allred, D Craig, Hunt, Kelly

“…Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive primary breast cancer triaged to chemotherapy when the…”
Get full text

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31 by PEREZ, Edith A, ROMOND, Edward H, SUMAN, Vera J, JEONG, Jong-Hyeon, DAVIDSON, Nancy E, GEYER, Charles E, MARTINO, Silvana, MAMOUNAS, Eleftherios P, KAUFMAN, Peter A, WOLMARK, Norman

“…Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). The clinical benefits of adjuvant trastuzumab have…”
Get full text

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine by Yu, Jia, Qin, Bo, Moyer, Ann M, Nowsheen, Somaira, Liu, Tongzheng, Qin, Sisi, Zhuang, Yongxian, Liu, Duan, Lu, Shijia W, Kalari, Krishna R, Visscher, Daniel W, Copland, John A, McLaughlin, Sarah A, Moreno-Aspitia, Alvaro, Northfelt, Donald W, Gray, Richard J, Lou, Zhenkun, Suman, Vera J, Weinshilboum, Richard, Boughey, Judy C, Goetz, Matthew P, Wang, Liewei

“…Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis that lacks targeted therapies, especially in patients with…”
Get full text

A comprehensive analysis of breast cancer microbiota and host gene expression by Thompson, Kevin J, Ingle, James N, Tang, Xiaojia, Chia, Nicholas, Jeraldo, Patricio R, Walther-Antonio, Marina R, Kandimalla, Karunya K, Johnson, Stephen, Yao, Janet Z, Harrington, Sean C, Suman, Vera J, Wang, Liewei, Weinshilboum, Richard L, Boughey, Judy C, Kocher, Jean-Pierre, Nelson, Heidi, Goetz, Matthew P, Kalari, Krishna R

“…The inflammatory tumoral-immune response alters the physiology of the tumor microenvironment, which may attenuate genomic instability. In addition to inducing…”
Get full text

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study by Bible, Keith C, Dr, Suman, Vera J, Prof, Molina, Julian R, MD, Smallridge, Robert C, Prof, Maples, William J, MD, Menefee, Michael E, MD, Rubin, Joseph, Prof, Sideras, Kostandinos, MD, Morris, John C, MD, McIver, Bryan, MB, Burton, Jill K, Webster, Kevin P, Bieber, Carolyn, Traynor, Anne M, MD, Flynn, Patrick J, MD, Goh, Boon Cher, MBBS, Tang, Hui, PhD, Ivy, Susan Percy, MD, Erlichman, Charles, Prof

“…Summary Background Chemotherapy has historically proven ineffective in advanced differentiated thyroid cancers, but the realisation that various tyrosine…”
Get full text

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031 by ELLIS, Matthew J, SUMAN, Vera J, ESSERMAN, Laura J, UNZEITIG, Gary W, MARGENTHALER, Julie, BABIERA, Gildy V, KELLY MARCOM, P, GUENTHER, Joseph M, WATSON, Mark A, LEITCH, Marilyn, HUNT, Kelly, OLSON, John A, HOOG, Jeremy, LI LIN, SNIDER, Jacqueline, PRAT, Aleix, PARKER, Joel S, JINGQIN LUO, DESCHRYVER, Katherine, CRAIG ALLRED, D

“…Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-positive breast cancer. To study this…”
Get full text

Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer by Perez, Edith A, Suman, Vera J, Davidson, Nancy E, Gralow, Julie R, Kaufman, Peter A, Visscher, Daniel W, Chen, Beiyun, Ingle, James N, Dakhil, Shaker R, Zujewski, Joanne, Moreno-Aspitia, Alvaro, Pisansky, Thomas M, Jenkins, Robert B

“…NCCTG (North Central Cancer Treatment Group) N9831 is the only randomized phase III trial evaluating trastuzumab added sequentially or used concurrently with…”
Get full text

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials by KORN, Edward L, LIU, Ping-Yu, PARULEKAR, Wendy, MARKOVIC, Svetomir N, SAXMAN, Scott, KIRKWOOD, John M, LEE, Sandra J, CHAPMAN, Judith-Anne W, NIEDZWIECKI, Donna, SUMAN, Vera J, MOON, James, SONDAK, Vernon K, ATKINS, Michael B, EISENHAUER, Elizabeth A

“…Objective tumor response rates observed in phase II trials for metastatic melanoma have historically not provided a reliable indicator of meaningful survival…”
Get full text

The where, when and what of phosphorus fertilisation for seedling establishment in a biodiverse jarrah forest restoration after bauxite mining in Western Australia by Tibbett, Mark, Daws, Matthew I., George, Suman J., Ryan, Megan H.

“…Fertiliser application to restore nutrients lost in the mining process and facilitate early plant establishment and growth is a key step in the restoration of…”
Get full text

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes by GOETZ, Matthew P, RAE, James M, DESTA, Zeruesenay, PEREZ, Edith A, INGLE, James N, SUMAN, Vera J, SAFGREN, Stephanie L, AMES, Matthew M, VISSCHER, Daniel W, REYNOLDS, Carol, COUCH, Fergus J, LINGLE, Wilma L, FLOCKHART, David A

“…Polymorphisms in tamoxifen metabolizing genes affect the plasma concentration of tamoxifen metabolites, but their effect on clinical outcome is unknown. We…”
Get full text

Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer by Hunt, Kelly K., Suman, Vera J., Wingate, Hannah F., Leitch, A. Marilyn, Unzeitig, Gary, Boughey, Judy C., Meric-Bernstam, Funda, Ellis, Matthew J., Olson, John

“…Background The ACOSOG Z1031 trial addressed the ability of three neoadjuvant aromatase inhibitors (NAIs) to reduce residual disease (cohort A) and to assess…”
Get full text

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer by Romond, Edward H, Perez, Edith A, Bryant, John, Suman, Vera J, Geyer, Charles E, Davidson, Nancy E, Tan-Chiu, Elizabeth, Martino, Silvana, Paik, Soonmyung, Kaufman, Peter A, Swain, Sandra M, Pisansky, Thomas M, Fehrenbacher, Louis, Kutteh, Leila A, Vogel, Victor G, Visscher, Daniel W, Yothers, Greg, Jenkins, Robert B, Brown, Ann M, Dakhil, Shaker R, Mamounas, Eleftherios P, Lingle, Wilma L, Klein, Pamela M, Ingle, James N, Wolmark, Norman

“…A combined analysis of two large studies found that the addition of trastuzumab to chemotherapy with doxorubicin and cyclophosphamide plus paclitaxel improved…”
Get full text

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2 -positive breast cancer (Z1041): a randomised, controlled, phase 3 trial by Buzdar, Aman U, Prof, Suman, Vera J, Prof, Meric-Bernstam, Funda, Prof, Leitch, A Marilyn, Prof, Ellis, Matthew J, Prof, Boughey, Judy C, MD, Unzeitig, Gary, MD, Royce, Melanie, Prof, McCall, Linda M, MS, Ewer, Michael S, Prof, Hunt, Kelly K, Prof

“…Summary Background Neoadjuvant chemotherapy with trastuzumab for patients with HER2 -positive breast cancer can produce a pathological complete response in the…”
Get full text

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations by Province, M A, Goetz, M P, Brauch, H, Flockhart, D A, Hebert, J M, Whaley, R, Suman, V J, Schroth, W, Winter, S, Zembutsu, H, Mushiroda, T, Newman, W G, Lee, M-T M, Ambrosone, C B, Beckmann, M W, Choi, J-Y, Dieudonné, A-S, Fasching, P A, Ferraldeschi, R, Gong, L, Haschke-Becher, E, Howell, A, Jordan, L B, Hamann, U, Kiyotani, K, Krippl, P, Lambrechts, D, Latif, A, Langsenlehner, U, Lorizio, W, Neven, P, Nguyen, A T, Park, B-W, Purdie, C A, Quinlan, P, Renner, W, Schmidt, M, Schwab, M, Shin, J-G, Stingl, J C, Wegman, P, Wingren, S, Wu, A H B, Ziv, E, Zirpoli, G, Thompson, A M, Jordan, V C, Nakamura, Y, Altman, R B, Ames, M M, Weinshilboum, R M, Eichelbaum, M, Ingle, J N, Klein, T E

“…The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical…”
Get full text

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial by PEREZ, Edith A, SUMAN, Vera J, WINER, Eric P, GELMON, Karen A, GERSH, Bernard J, JAFFE, Allan S, RODEHEFFER, Richard J, DAVIDSON, Nancy E, SLEDGE, George W, KAUFMAN, Peter A, HUDIS, Clifford A, MARTINO, Silvana, GRALOW, Julie R, DAKHIL, Shaker R, INGLE, James N

“…To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial. Patients…”
Get full text

Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM by Goetz, Matthew P, Suman, Vera J, Nakamura, Yusuke, Kiyotani, Kazuma, Jordan, V Craig, Ingle, James N

Get full text

Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models by Hart, Steven N., Hoskin, Tanya, Shimelis, Hermela, Moore, Raymond M., Feng, Bingjian, Thomas, Abigail, Lindor, Noralane M., Polley, Eric C., Goldgar, David E., Iversen, Edwin, Monteiro, Alvaro N.A., Suman, Vera J., Couch, Fergus J.

“…To improve methods for predicting the impact of missense variants of uncertain significance (VUS) in BRCA1 and BRCA2 on protein function. Functional data for…”
Get full text

HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial by PEREZ, Edith A, SUMAN, Vera J, DAVIDSON, Nancy E, MARTINO, Silvana, KAUFMAN, Peter A, LINGLE, Wilma L, FLYNN, Patrick J, INGLE, James N, VISSCHER, Daniel, JENKINS, Robert B

“…To evaluate concordance between local and central laboratory HER2 testing results in patients from the North Central Cancer Treatment Group (NCCTG) N9831…”
Get full text